BC
ASMB icon

Broadfin Capital’s Assembly Biosciences ASMB Stock Holding History

Broadfin Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-30,831
Closed -$7.07M – 86
2013
Q4 		$7.07M Hold
30,831
– – 0.93% 35
2013
Q3 		$5.35M Hold
30,831
– – 0.95% 31
2013
Q2 		$4.44M Buy
+30,831
New +$4.83M 0.87% 29

Other funds holding ASMB

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Broadfin Capital's ASMB Position: Q1 2014 in Review

Broadfin Capital sold out of Assembly Biosciences (ASMB) in Q1 2014, closing a stake of 30,831 shares — an estimated $7.07M sold.

Broadfin Capital first reported a position in ASMB in Q2 2013 and held it in 3 quarters. The position peaked at $7.07M in Q4 2013. 28 funds tracked by Wall St. Rank hold ASMB as of Q1 2014.

  • Broadfin Capital reported no remaining Assembly Biosciences position as of Q1 2014 after selling out during the quarter.
  • Broadfin Capital sold 30,831 Assembly Biosciences shares in Q1 2014, an estimated $7.07M.
  • Broadfin Capital first reported a position in Assembly Biosciences in Q2 2013 and held it in 3 quarters.
  • Broadfin Capital's Assembly Biosciences position peaked at $7.07M in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2014.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.